Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05701527 · ClinicalTrials.gov registry record · Phase 1

A Study of EBC-129 in Advanced Solid Tumours

A Phase 1 study of Advanced Solid Tumours, sponsored by EDDC (Experimental Drug Development Centre), A*STAR Research Entities.

Recruiting
Registry status
Phase 1
Development phase
98
Enrollment target
5
Study locations

NCT05701527: Recruiting Phase 1 study of Advanced Solid Tumours, sponsored by EDDC (Experimental Drug Development Centre), A*STAR Research Entities.

NCT05701527 is a Phase 1 study of Advanced Solid Tumours that is actively recruiting participants, run by EDDC (Experimental Drug Development Centre), A*STAR Research Entities. The registered enrollment target is 98 participants, below the 227-participant average among 3 other Advanced Solid Tumours trials with a reported enrollment target (57% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05701527, a Phase 1 study of Advanced Solid Tumours, is actively recruiting participants, sponsored by EDDC (Experimental Drug Development Centre), A*STAR Research Entities.

RECRUITING
Registry status
Phase 1
Development phase
98 participants
Enrollment target
5
Study locations

Study Summary

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

Conditions Studied

Advanced Solid Tumours

Interventions

  • DRUG Pembrolizumab
  • DRUG EBC-129

Study Locations (5)

South West

  • National University Hospital - Medical Oncology - Singapore
  • National Cancer Centre Singapore - Singapore

Colorado

  • University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center - Aurora

Texas

  • UT MD Anderson Cancer Center - Houston

Taipei

  • Taipei Veterans General Hospital - Taipei

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2023-04-28
Est. Completion 2026-12-24
Phase Phase 1
EDDC (Experimental Drug Development Centre), A*STAR Research Entities

2 total trials

What NCT05701527 shows while recruiting

NCT05701527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 227-participant average among 3 other Advanced Solid Tumours trials with a reported enrollment target (57% lower).

The record links to 1 condition, with Advanced Solid Tumours appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05701527 lists 5 locations in 4 states (South West, Colorado, Texas).

Frequently Asked Questions

What is clinical trial NCT05701527 about?

NCT05701527 is a clinical study titled "A Study of EBC-129 in Advanced Solid Tumours". This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

What is the current status of trial NCT05701527?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2023-04-28. Estimated completion is 2026-12-24.

What conditions does trial NCT05701527 study?

This clinical trial studies the following conditions: Advanced Solid Tumours.

What interventions are being tested in trial NCT05701527?

The interventions under investigation include: Pembrolizumab (DRUG), EBC-129 (DRUG).

Who is sponsoring clinical trial NCT05701527?

This trial is sponsored by EDDC (Experimental Drug Development Centre), A*STAR Research Entities, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05701527 being conducted?

This trial has 5 study locations across Colorado, Texas, South West, Taipei. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumours

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02926729 · 98 participants · NA

    Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy

  • NCT03382977 · 98 participants · Phase 1

    Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

  • NCT04577014 · 98 participants · Phase 1

    Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

  • NCT04817618 · 98 participants · Phase 3

    Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05701527

Source: ClinicalTrials.gov NCT05701527, the US trial registry maintained by the National Library of Medicine. NCT05701527 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.